Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950170-25-041642·Keenova Therapeutics plc
Schedule 13D ownership disclosure
Keenova Therapeutics PLC
Common Stock, par value $0.01 per share · CUSIP: G5890A102
Event date: 2025-03-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Silver Point Capital, L.P.Reported CIK 0001332784
Shares: 1,692,330 · Class: 8.6%
- Edward A. MuleReported CIK 0001029625
Shares: 1,692,330 · Class: 8.6%
- Robert J. O'SheaReported CIK 0001382617
Shares: 1,692,330 · Class: 8.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-041642
- Form type
- SCHEDULE 13D/A
- Filer
- Keenova Therapeutics plc
- CIK
- CIK 1567892
- Filed
- Mar 18, 2025
- Reporting period
- Mar 13, 2025
- Description
- Schedule 13D beneficial ownership